Afify A, Mark H F
Department of Pathology, Rhode Island Hospital, Providence 02903, USA.
Cancer Genet Cytogenet. 1997 Sep;97(2):101-5. doi: 10.1016/s0165-4608(96)00361-5.
A total of 34 cases of infiltrating ductal carcinoma of the breast, not otherwise specified (NOS), were selected, based on the clinical stage of the disease (17 cases stage I and 17 cases stage II). The histologic grade and the DNA content of each tumor were evaluated. Each specimen was analyzed and blinded cytogenetically for the frequency of chromosome 8 copy number using fluorescence in situ hybridization (FISH). Among the informative samples, 16 cases were disomic (47%) and 18 cases (53%) were trisomic. Of the 16 disomic tumors, 13 cases (81%) were classified clinically as stage I disease and 3 cases (19%) were stage II disease. Of the 18 trisomic tumors, 4 cases (22%) were stage I, and 14 cases (78%) were stage II. Microscopically, all trisomic tumors were of high histologic grade and aneuploid when analyzed by flow cytometry. We inferred from these data that a subset of infiltrating ductal carcinomas (NOS) is characterized by chromosome 8 trisomy. This chromosomal abnormality correlates well with other markers that predicate aggressive biological behavior of the tumor. While this observation needs to be further extended, the data suggest that chromosome 8 copy number may be used as a possible marker to identify a subgroup of patients with infiltrating ductal carcinoma associated with a poor prognosis.
共选取34例未另行特殊说明的乳腺浸润性导管癌（NOS）病例，根据疾病临床分期（17例I期和17例II期）进行分组。评估每个肿瘤的组织学分级和DNA含量。使用荧光原位杂交（FISH）对每个标本进行分析，并在细胞遗传学方面进行盲法检测，以确定8号染色体拷贝数频率。在信息充分的样本中，16例为二体（47%），18例为三体（53%）。在16例二体肿瘤中，13例（81%）临床分类为I期疾病，3例（19%）为II期疾病。在18例三体肿瘤中，4例（22%）为I期，14例（78%）为II期。显微镜下，所有三体肿瘤经流式细胞术分析均为高组织学分级且非整倍体。我们从这些数据推断，一部分乳腺浸润性导管癌（NOS）的特征是8号染色体三体。这种染色体异常与预示肿瘤侵袭性生物学行为的其他标志物密切相关。虽然这一观察结果需要进一步扩展，但数据表明8号染色体拷贝数可能用作识别预后不良的乳腺浸润性导管癌患者亚组的一种可能标志物。
